CVS Health to Split Into Two Independent Companies by 2028
CVS Health reported Q3 adjusted EPS of $2.09, topping estimates, and raised full-year guidance to at least $8.20 as it plans to split into two companies by 2028.
CVS Health reported Q3 adjusted EPS of $2.09, topping estimates, and raised full-year guidance to at least $8.20 as it plans to split into two companies by 2028.
Sanofi has terminated the SAR448272 STAT6 degrader program. Nurix shares fell sharply in after-hours trading, but cash runway remains intact through 2029.
Karyopharm has filed for Chapter 11 to pursue a merger with Ayrmid, securing $55 million in financing while continuing myeloma and myelofibrosis programs.
After earlier setbacks, FDA grants Priority Review to uniQure’s AMT-130 as a potential first disease-modifying Huntington’s treatment.
Bright Minds says FDA partial hold on its BMB-101 DEE study is limited to the planned U.S. trial and does not affect other programs.
INOVIO’s VOCERYQ receives FDA accelerated approval as the first DNA medicine in the US, reducing surgery frequency in adults with recurrent respiratory papillomatosis.